Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series
This study demonstrated that neoadjuvant FEC followed by triweekly docetaxel and/or trastuzumab did induce a high pathologic response in luminal HER2 type, but not in luminal A and B types, and did not induce a high pCR rate in the hormone-positive patients.Keywords: luminal type, surgery, therapeutic efficacy
Source: Vascular Health and Risk Management - Category: Cardiology Tags: Breast Cancer: Targets and Therapy Source Type: research
More News: Breast Cancer | Breast Carcinoma | Breast Surgery | Cancer | Cancer & Oncology | Carcinoma | Cardiology | Chemotherapy | Docetaxel | Ductal Carcinoma | Health | Hematology | HER2 | Herceptin | Hormones | Hospital Management | Hospitals | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Study | Taxotere | Toxicology | Women